Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma

Klinichescheskaya Laboratornaya Diagnostika

Volumn , Issue 10, 2013, Pages 34-37

  Makarova, A S ^a   Lazarevich, N L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898430788     PISSN: 08692084     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ferlay J., Shin H. R., Bray F, Forman D., Mathers C., Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010;127(12):2893-917.
2. ElSerag H. B., Rudolph K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76.
3. Aravalli R. N., Steer C. J., Cressman E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):1049-53.
4. Aravalli R. N., Cressman E. N., Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Archio Toxicol. 2013;87(2):227-47.
5. Marquardt J. U., Galle P. R., Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J. Hepatol. 2012;56(1):267-75.
6. Whittaker S., Marais R., Zhu A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29(36):4989-5005.
7. Breuhahn K., Longerich T., Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25(27):3787-800.
8. Forner A., Llovet J. M., Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245-55.
9. Villanueva A., Chiang D. Y., Newell P., Peix J., Thung S., Alsinet C. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972-83, 1983. e1-11.
10. Tovar V, Alsinet C., Villanueva A., Hoshida Y., Chiang D. Y., Solé M. et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. Hepatol. 2010;52(4):550-9.
11. Coulouarn C., Factor V. M., Thorgeirsson S. S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47(6):2059-67.
12. Lachenmayer A., Alsinet C., Scrvic R., Cabellos L., Toffanin S., Hoshida Y. et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 2012;18(18):4997-5007.
13. Kaposi-Novak P., Lee J. S., Gòmez-Quiroz L., Coulouarn C, Factor V. M., Thorgeirsson S. S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006;116(6):1582-95.
14. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J. Angiogenesis in liver disease. J. Hepatol. 2009;50(3):604-20.
15. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R. A. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006;5:835-44.
16. Wilhelm S. M., Adnane L., Newell P., Villanueva A., Llovet J. M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008;7(10):3129-40.
17. Iyer R., Fetterly G., Lugade A., Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert. Opin. Pharmacother. 2010;11(11):1943-55.
18. Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-109.
19. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851-58.
20. Chen K. F., Tai W. T., Liu T. H., Huang H. P., Lin Y. C., Shiau C. W. et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 2010;16:5189-99.
21. Fernando J., Sancho P., Fernández-Rodriguez C. M., LledóJ. L., Caja L. et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J. Cell. Physiol. 2012;227(4):1319-25.
22. Rosmorduc O., Desbois-Mouthon C. Targeting STAT3 in hepatocellular carcinoma: Sorafenib again. J. Hepatol. 2011;55:957-59.
23. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21:159-68.
24. He G., Vu G. Y., Temkin K, Ogata H., Kunlzen C., Sakurai T. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17(3):286-97.
25. Tai W. T., Cheng A. L., Shiau C. W., Huang H. P., Huang J. W., Chen P. J. et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 2011;55(5):1041-48.
26. Cervello M., McCubrey J. A., Cusimano A., Lampiasi N., Azzolina A., Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012;3(3):236-60.
27. Serova M., de Gramont A., Tijeras-Raballand A., Dos Santos C., Riveiro M. E., Slimane K. et al. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother. Pharmacol. 2013;71(5):1297-307.
28. Blivet-Van Eggelpoel M. J., Chettouh H., Fartoux L., Aoudjehane L., Barbu V., Rey C. et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J. Hepatol. 2012;57(1):108-15.
29. Castillo J., Erroba E., Perugorria M. J., Santamaria M., Lee D. C., Prieto J. et al. Amphiregulin Contributes to the Transformed Phenotype of Human Hepatocellular Carcinoma Cells. Cancer Res. 2006;66:6129-38.
30. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
31. van Zijl F, Mall S., Machat G., Pirker C., Zeillinger R., Weinhaeusel A. et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol. Cancer Ther. 2011;10(5):850-60.
32. Lazarevich N. L., Shavochkina D. A., Fleishman D. I., Kustova I. F., Morozova O. V., Chuchuev E. S. et al. Deregulation of hepatocyte nuclear factor 4 (HNF4) as a marker of epithelial tumors progression. Exp. Oncol. 2010;32(3):167-71.
33. Xin H. W., Ambe C. M., Hari DM., Wiegand G. W., Miller T. C., Chen J. Q. et al. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut; 2013; Feb. 14. Available at: http://gut.bmj.com/content/early/2013/02/13/ gutjnl-2012-303261.abstract?sid=ld0cf7c2-dfdd-4e10-9b2d-b4e4f8f433b7
34. Majumdar A., Curley S. A., Wu X., Brown P., Hwang J. P., Shetty K. et al. Hepatic stem cells and transforming growth factor P in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012;9(9):530-8.
35. Marquardt J. U., Thorgeirsson S. S. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin. Liver Dis. 2010;30(1):26-34.